Sai Parenterals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.4K Cr
Sai Parenterals targets Rs. FY '27 guidance: Revenue target of Rs.
From Sai Parenterals Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Price
₹531
Market Cap
₹2.4K Cr
P/E Ratio
115.1
Revenue Rank
Rank 3
Margin Rank
Rank 3
How does Sai Parenterals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sai Parenterals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Revenue: Rank 3Margin: Rank 3
Sai Parenterals Ltd — Quarterly revenue & net profit
Revenue Net Profit
Dec 2025
Mar 2026
Reported quarterly figures (₹ Cr). Latest: revenue ₹198 Cr, net profit ₹13 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Sai Parenterals targets Rs. 750 crore revenue for FY '27 with 17% EBITDA margin, expecting the year to be weighted towards the second half.
- →FY '27 is considered a building year; significant growth anticipated from FY '28 as new assets and acquisitions begin contributing to earnings and cash flows.
- →Noumed expansion expects additional order wins, including a large AUD 202 million contract, with new product developments adding incremental revenue beyond existing orders.
- →The new EU-GMP injectable facility and R&D acquisition will boost capacity and product offerings, particularly in regulated markets (Europe, ROW).
- →US market entry through a newly formed subsidiary is in preliminary evaluation; potential contribution remains under assessment.
- →Injectable segment growth expected via lyophilized, liposomal, oncology, and critical-care products marketed in new geographies.
- →Debt planned to peak in FY '27 with deleveraging from FY '28 onwards enhancing financial strength to support growth.
📈 Profitability & Margins
Rank 3- →FY '27 guidance: Revenue target of Rs. 750 crores with EBITDA margin around 17%, weighted towards the second half.
- →EBITDA expected to improve smoothly post Q1 FY '27 with supply disruptions resolved.
- →FY '28 outlook: Management prefers to wait and assess performance over next quarters before revising guidance.
- →Peak debt expected in FY '27 due to CAPEX and acquisitions; de-leveraging anticipated from FY '28 as assets contribute to earnings and cash flows.
- →Debt to equity ratio anticipated around 0.6 times, indicating manageable leverage.
- →Noumed acquisition and new manufacturing capacities expected to enhance future revenue and margins.
- →Potential US market entry is at an early stage; future contributions not yet determined.
- →Overall, growth expected from expanded product capacity, acquisitions, and new markets with cautious approach to financial performance updates.
🏗️ Capital Expenditure Plans
Yes- →Rs. 83.83 crores invested for a 60% equity stake in Saicriti Pharma Pvt Ltd to build a critical care injectable facility at Gummadidala, Hyderabad (EU GMP and USFDA standards).
- →Total project cost of Rs. 217 crores; balance 40% funded by Saicriti promoters and additional project debt.
- →Acquisition of 60% equity in Prathyak Laboratories for Rs. 15 crores to gain an operational R&D center with 150 SKUs across 86 molecules, accelerating product development.
- →AUD 5 million funding to complete Australian facility; AUD 3.5 million contributed via Singapore subsidiary.
- →Proposal to establish a US subsidiary via Singapore for market entry (currently under evaluation).
- →Capital expenditure shifted from upgrading existing Units 1 and 2 to acquiring and developing new facilities due to regulatory/permitting constraints.
- →Project completion targets: Saicriti facility by April 2027; Australian facility physical completion by January 2027 with Phase 1 manufacturing from April 2027.
💰 Fundraising & Capital Structure
Yes- →Current debt as of June 2027 is around Rs. 310 crores, down from Rs. 320 crores in March 2026, after repaying Rs. 50 crores of loans using IPO proceeds.
- →Incremental debt is expected for the Saicriti acquisition, which will follow a 60%-40% equity-to-debt funding ratio.
- →Peak debt for the group is anticipated in FY '27 due to ongoing CAPEX and acquisitions.
- →The projected peak gross debt-to-equity ratio is around 0.6 times, considered comfortably placed.
- →Post FY '27, the company plans gradual de-leveraging as new assets start contributing earnings and cash flows.
- →No mention of immediate future equity fundraising; current focus is on debt management and strategic investments through existing funds and project debt.
📋 Order Book & Pipeline
Yes- →Noumed Pharmaceuticals has secured a significant order from a pharmacy chain in Australia valued at AUD 202 million for the next 12 months.
- →This order includes existing products and excludes 12 newer drugs under development, which are expected to add to future order values.
- →Noumed anticipates ongoing yearly order wins of similar scale, supported by a standard year-on-year growth of 5%-8% in pharmacy network expansion.
- →The current order value represents a forecasted run rate, with additional new product developments (NPDs) expected to be added annually.
- →Noumed is engaging with several multinational clients for Contract Manufacturing Organization (CMO) opportunities, indicating potential future order growth.
Key Metrics
Revenue
Rank 3
Margin
Rank 3
Capex
Yes
Fundraise
Yes
Order Book
Yes
Frequently Asked Questions
What were Sai Parenterals Ltd Q1 FY27 results?
Sai Parenterals targets Rs. FY '27 guidance: Revenue target of Rs.
What is Sai Parenterals Ltd share price analysis?
Sai Parenterals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 115.1 with a market cap of ₹2,389 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Parenterals Ltd planning capital expenditure?
Rs.
Keep Sai Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.